Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.
Rie von EybenManuela Andrea HoffmannCigdem SoydalIrene J VirgoliniMurat TuncelMathieu GauthéDaniel S KappFinn Edler von EybenPublished in: Biomedicines (2023)
The pretest PSA and PSMA PET/CT were important for the OS of the BCR patients. The findings argue for the new BCR risk model and serve as framework for ongoing trials.